European Cystic Fibrosis Society 2022
In June 2022, Prof. McNally presented the 12 month RECOVER data from the 12+ patients at the ECFS Conference in Rotterdam. This data showed that ELX/TEZ/IVA is associated with significant and sustained improvements in an array of outcome measures in people with CF. A significant proportion (40%) of people in the homozygous deltaF508 group had a sweat chloride in the normal range on treatment. Data collection is continuing for RECOVER and we hope to present more findings and study updates at future conferences.
Another poster was presented at the ECFS by our project manager Karen Lester on behalf of Sharon Sutton. This poster looked at the medication adherence of patients who commenced on ELX/TEZ/IVA from baseline to 6-months on treatment. This data showed that self reported questionnaires and medication pick up rates overestimate treatment adherence when compared with Medication Electronic Monitoring System (MEMS®). Data collection is ongoing for the 12+ cohort, with recruitment of the 6+ anticipated over the coming months.
Prof. Mainz present the below data at the ECFS. He is looking at the effect of ETI on the abdominal symptoms of people with CF.
